Herpes simplex virus type 2, genital ulcers and HIV-1 disease progression in postpartum women

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Roxby, Alison C ^a   Drake, Alison L ^a   John Stewart, Grace ^a   Brown, Elizabeth R ^a   Matemo, Daniel ^b   Otieno, Phelgona A ^c   Farquhar, Carey ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; VIRUS RNA; ZIDOVUDINE; VIRUS ANTIBODY;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE COURSE; FEMALE; GENITAL ULCER; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; NONHUMAN; OPPORTUNISTIC INFECTION; PREGNANT WOMAN; PUERPERIUM; RETROSPECTIVE STUDY; SEROLOGY; SURVIVAL; BLOOD; GENITAL HERPES; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; KAPLAN MEIER METHOD; KENYA; PHYSIOLOGY; PREGNANCY; RISK FACTOR; ULCER; VIROLOGY;

HUMAN HERPESVIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTIBODIES, VIRAL; DISEASE PROGRESSION; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIER ESTIMATE; KENYA; OPPORTUNISTIC INFECTIONS; POSTPARTUM PERIOD; PREGNANCY; RISK FACTORS; RNA, VIRAL; ULCER; YOUNG ADULT;

EID: 79957553104     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019947     Document Type: Article

References (28)

1. Bollen LJ, Whitehead SJ, Mock PA, Leelawiwat W, Asavapiriyanont S, et al. (2008) Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission? AIDS 22: 1169-1176.
2. Cowan FM, Humphrey JH, Ntozini R, Mutasa K, Morrow R, et al. (2008) Maternal Herpes simplex virus type 2 infection, syphilis and risk of intra-partum transmission of HIV-1: results of a case control study. AIDS 22: 193-201.
3. John GC, Nduati RW, Mbori-Ngacha DA, Richardson BA, Panteleeff D, et al. (2001) Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 183: 206-212.
4. Drake AL, John-Stewart GC, Wald A, Mbori-Ngacha DA, Bosire R, et al. (2007) Herpes simplex virus type 2 and risk of intrapartum human immunodeficiency virus transmission. Obstet Gynecol 109: 403-409.
5. Hitti J, Watts DH, Burchett SK, Schacker T, Selke S, et al. (1997) Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. Am J Obstet Gynecol 177: 450-454.
6. Walson JL, Brown ER, Otieno PA, Mbori-Ngacha DA, Wariua G, et al. (2007) Morbidity among HIV-1-infected mothers in Kenya: prevalence and correlates of illness during 2-year postpartum follow-up. J Acquir Immune Defic Syndr 46: 208-215.
7. Brocklehurst P, French R, (1998) The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 105: 836-848.
8. Watson-Jones D, Weiss HA, Changalucha JM, Todd J, Gumodoka B, et al. (2007) Adverse birth outcomes in United Republic of Tanzania-impact and prevention of maternal risk factors. Bull World Health Organ 85: 9-18.
9. Serwadda D, Gray RH, Sewankambo NK, Wabwire-Mangen F, Chen MZ, et al. (2003) Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis 188: 1492-1497.
10. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, et al. (2010) Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 362: 427-439.
11. Sheth PM, Sunderji S, Shin LY, Rebbapragada A, Huibner S, et al. (2008) Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. J Infect Dis 197: 1394-1401.
12. Schacker T, (2001) The role of HSV in the transmission and progression of HIV. Herpes 8: 46-49.
13. Duffus WA, Mermin J, Bunnell R, Byers RH, Odongo G, et al. (2005) Chronic herpes simplex virus type-2 infection and HIV viral load. Int J STD AIDS 16: 733-735.
14. Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, et al. (2008) Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 198: 1804-1808.
15. Delany S, Mlaba N, Clayton T, Akpomiemie G, Capovilla A, et al. (2009) Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 23: 461-469.
16. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, et al. (2007) Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 356: 790-799.
17. Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al. (2007) Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 196: 1500-1508.
18. Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, et al. (2006) Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 20: 2305-2313.
19. Dunne EF, Whitehead S, Sternberg M, Thepamnuay S, Leelawiwat W, et al. (2008) Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 49: 77-83.
20. Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, et al. (2010) Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 375: 824-833.
21. Emery S, Bodrug S, Richardson BA, Giachetti C, Bott MA, et al. (2000) Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol 38: 2688-2695.
22. Otieno PA, Brown ER, Mbori-Ngacha DA, Nduati RW, Farquhar C, et al. (2007) HIV-1 disease progression in breast-feeding and formula-feeding mothers: a prospective 2-year comparison of T cell subsets, HIV-1 RNA levels, and mortality. J Infect Dis 195: 220-229.
23. Gray RH, Li X, Wawer MJ, Serwadda D, Sewankambo NK, et al. (2004) Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J Infect Dis 189: 1209-1215.
24. Aumakhan B, Gaydos CA, Quinn TC, Beyrer C, Benning L, et al. (2010) Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers. PLoS One 5: e9973.
25. Collier AC, Bozzette S, Coombs RW, Causey DM, Schoenfeld DA, et al. (1990) A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med 323: 1015-1021.
26. Cooper DA, Pehrson PO, Pedersen C, Moroni M, Oksenhendler E, et al. (1993) The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group. AIDS 7: 197-207.
27. Stein DS, Graham NM, Park LP, Hoover DR, Phair JP, et al. (1994) The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study. Ann Intern Med 121: 100-108.
28. Ioannidis JP, Collier AC, Cooper DA, Corey L, Fiddian AP, et al. (1998) Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 178: 349-359.